Filing summary
Entity discrepancy: The request identifies Tectonic Therapeutic, Inc., but the supplied Form 10-Q is for AVROBIO, Inc. (Nasdaq: AVRO). This summary reflects the supplied filing, for the quarter ended June 30, 2019, filed August 8, 2019.
Business context and reporting period
AVROBIO is a clinical-stage gene therapy company developing ex vivo lentiviral therapies for rare diseases. Its pipeline included AVR-RD-01 for Fabry disease, AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-03 for Pompe disease. The company had no approved products and generated no product revenue. Financial statements are unaudited; amounts below are in millions unless stated otherwise.
Financial performance and position
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $12.3 | $7.4 | $24.7 | $13.1 |
| General and administrative expense | $4.3 | $2.1 | $9.6 | $4.3 |
| Total operating expenses | $16.6 | $9.5 | $34.3 | $17.3 |
| Net loss | $16.1 | $10.5 | $33.2 | $18.7 |
| Operating cash used | Not stated quarterly | Not stated quarterly | $35.7 | $14.2 |
Gross and operating margins are not meaningful because the company reported no revenue. Q2 expenses rose as research and development programs, staffing, facilities, and public-company costs expanded. Interest income was $0.6 million for Q2 and $1.2 million for the first half; the prior-year periods included noncash fair-value expenses on liabilities related to the IPO that did not recur in 2019.
At June 30, 2019, cash and cash equivalents were $90.3 million, current assets $98.2 million, current liabilities $8.8 million, total liabilities $9.4 million, and stockholders’ equity $92.6 million. The balance sheet reports no borrowings. Cash, cash equivalents, and restricted cash declined $36.0 million during the first half. The company reported an accumulated deficit of $104.9 million.
Material changes and financing
- First-half net loss increased $14.4 million year over year, while operating cash use increased $21.5 million.
- First-half R&D spending increased $11.7 million, with higher costs across Gaucher, Pompe, and cystinosis programs and unallocated research and development.
- In July 2019, after quarter-end, AVROBIO completed an offering of 7.475 million shares at $18.50 per share, raising approximately $129.5 million net. Management estimated that June-end cash plus the offering proceeds would fund planned operations into the second half of 2021; this estimate depends on assumptions that could prove inaccurate.
- The company also established a $200 million shelf registration and a $50 million at-the-market sales agreement. As of June 30, common shares outstanding were 24.1 million; the filing reported 31.7 million outstanding as of August 5.
Outlook, clinical developments, risks, and unusual items
- Management expected expenses to increase as clinical studies and manufacturing development advanced. The company anticipated no product revenue in the near future and stated that additional capital would ultimately be needed.
- In July 2019, AVROBIO reported interim AVR-RD-01 results: one Phase 2 patient had an 87% reduction in kidney Gb3 inclusions and plasma lyso-Gb3 at one year; four Phase 1 patients showed 33%–41% reductions in plasma lyso-Gb3 versus their baseline ERT levels. These are preliminary observations from very small patient groups, not evidence of established efficacy.
- The filing reported no drug-product-related serious adverse events among the eight Fabry patients dosed as of the stated data cutoffs. Six serious adverse events were reported across the trials, attributed to conditioning, underlying disease, or pre-existing conditions; all were reported as resolved. Conditioning-related risks and the planned transition to busulfan with therapeutic drug monitoring remain important safety considerations.
- AVR-RD-02 recruitment had begun, with first dosing expected in the second half of 2019. The cystinosis study also had active recruitment and first dosing was expected in the second half of 2019; a $12 million CIRM grant was announced to fund that trial phase. Pompe remained in early preclinical development.
- The company was transitioning to its plato platform, including an optimized LV2 vector, closed automated manufacturing, and a revised conditioning regimen. The platform had not yet been used to dose patients, and comparability, manufacturing scale-up, regulatory review, and clinical performance were risks.
- Disclosure controls were deemed ineffective at June 30 because material weaknesses remained in financial close, complex accounting judgments, expense classification, cash disbursements, and accrued R&D expense controls. The filing also described a 2017 cyberattack involving theft of funds and a February 2019 vendor cyberattack that led to payment of a fraudulent invoice.
- No material legal proceedings were reported. License agreements include potential milestone and royalty obligations; a $2 million GenStem milestone would be triggered by first treatment of a cystinosis trial patient. The filing also described unlimited potential exposure under certain indemnification agreements, though management did not anticipate significant losses.
Most important facts for investors to verify
- Confirm that AVROBIO, rather than Tectonic Therapeutic, is the intended filing and issuer.
- Review the July 2019 offering’s net proceeds, share dilution, and the assumptions behind the stated runway into the second half of 2021.
- Assess the full clinical data, patient follow-up, and safety profile for AVR-RD-01; distinguish preliminary company-reported results from controlled or confirmatory evidence.
- Track whether the plato/LV2 manufacturing transition and busulfan conditioning are implemented as planned and whether they affect trial timing, comparability, or safety.
- Monitor remediation of the disclosed material weaknesses and the company’s safeguards against payment fraud and cyberattacks.
- Check trial enrollment and dosing milestones, future cash burn, and potential license-related milestone payments, particularly the cystinosis milestone.